middle.news
Recce Pharmaceuticals Boosts Cash with A$3.7 Million Tax Refund Ahead of Phase 3 Trials
9:07am on Wednesday 1st of July, 2026 AEST
•
Healthcare
Read Story
Recce Pharmaceuticals Boosts Cash with A$3.7 Million Tax Refund Ahead of Phase 3 Trials
9:07am on Wednesday 1st of July, 2026 AEST
Key Points
A$3.7 million tax refund from FY2025 R&D expenditure
Pro-forma cash position rises to around A$33.1 million
Upcoming A$7.5 million R&D Tax Incentive rebate expected
Recent capital raise and Share Purchase Plan underway
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE